Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare Disease Research: Where Compassion Meets Commerce

This article was originally published in Start Up

Executive Summary

The advent of a new set of potential acquirers has heightened venture capital's interest in rare diseases, resulting in the creation of a new cohort of drug developers that are using cutting edge technologies to treat and in some cases cure grave illnesses. In this issue, we profile Afraxis, bluebird bio, Edimer Pharmaceuticals and Ultragenyx Pharmaceutical.
Advertisement

Related Content

Rare Disease Specialist Ultragenyx Takes $45MM Series A Round
Edimer Pharmaceuticals Inc.
Start-Up Previews (05/2011)
Afraxis Inc.
bluebird bio LLC
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Valuing Genzyme: A Health Care Reform Premium
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene
Shire: Remodeling Specialty Pharma

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel